Ophthalmic pharmaceutical and medical technology company Glaukos Corporation (NYSE:GKOS) on Friday announced positive topline results from its Phase 4 GLK-101-04 clinical trial evaluating iDose TR in combination with cataract surgery in patients with open-angle glaucoma or ocular hypertension.
The study met its primary efficacy endpoint, with the combination delivering a mean diurnal intraocular pressure (IOP) reduction of 11.1 mmHg at three months, compared with 7.4 mmHg for cataract surgery alone, representing a statistically significant difference of 3.6 mmHg.
iDose TR also demonstrated statistically significant superiority across all prespecified secondary responder analyses and a favourable safety profile through three months, with no treatment-related corneal endothelial cell loss, cystoid macular oedema or serious corneal adverse events.
The randomised, double-masked trial included 149 study eyes, with 74 assigned to the combination treatment group and 75 to cataract surgery alone.
iDose TR is an intracameral therapy designed to deliver therapeutic levels of travoprost continuously for up to three years, with the aim of addressing patient non-adherence and chronic side effects associated with topical glaucoma medications.
Ribo submits European Clinical Trial Application for SR122 in mixed and severe dyslipidaemia
Spermosens and Genea agree IVF study of JUNO-Checked in Australia
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
Charles River Laboratories to acquire Frontage bioanalysis and DMPK businesses for USD470m
UCB and Biogen report additional positive Phase 3 data for investigational lupus treatment
Valneva reports positive Phase 2 results for tetravalent Shigella vaccine candidate
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease